Switch theme
Sign up to access all valuation multiples
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
1999
92
LTM Revenue $19.4M
Last FY EBITDA -$174M
$3.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Soleno Therapeutics has a last 12-month revenue (LTM) of $19.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Soleno Therapeutics achieved revenue of n/a and an EBITDA of -$174M.
Soleno Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Soleno Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $19.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $17.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$174M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$166M | XXX | -$184M | XXX | XXX | XXX |
| EBIT Margin | -854% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$158M | XXX | -$176M | XXX | XXX | XXX |
| Net Margin | -815% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Soleno Therapeutics's stock price is $73.
Soleno Therapeutics has current market cap of $3.7B, and EV of $3.5B.
See Soleno Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.5B | $3.7B | XXX | XXX | XXX | XXX | $-3.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Soleno Therapeutics has market cap of $3.7B and EV of $3.5B.
Soleno Therapeutics's trades at n/a EV/Revenue multiple, and -19.9x EV/EBITDA.
Equity research analysts estimate Soleno Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Soleno Therapeutics has a P/E ratio of -23.4x.
See valuation multiples for Soleno Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $3.5B | XXX | $3.5B | XXX | XXX | XXX |
| EV/Revenue | 178.2x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -19.9x | XXX | XXX | XXX |
| EV/EBIT | -20.9x | XXX | -18.8x | XXX | XXX | XXX |
| EV/Gross Profit | 192.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -23.4x | XXX | -21.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -49.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSoleno Therapeutics's last 12 month revenue growth is 650%
Soleno Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Soleno Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Soleno Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Soleno Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 650% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Soleno Therapeutics acquired XXX companies to date.
Last acquisition by Soleno Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Soleno Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Soleno Therapeutics founded? | Soleno Therapeutics was founded in 1999. |
| Where is Soleno Therapeutics headquartered? | Soleno Therapeutics is headquartered in United States of America. |
| How many employees does Soleno Therapeutics have? | As of today, Soleno Therapeutics has 92 employees. |
| Who is the CEO of Soleno Therapeutics? | Soleno Therapeutics's CEO is Dr. Anish Bhatnagar, M.D.. |
| Is Soleno Therapeutics publicy listed? | Yes, Soleno Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Soleno Therapeutics? | Soleno Therapeutics trades under SLNO ticker. |
| When did Soleno Therapeutics go public? | Soleno Therapeutics went public in 2014. |
| Who are competitors of Soleno Therapeutics? | Similar companies to Soleno Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Soleno Therapeutics? | Soleno Therapeutics's current market cap is $3.7B |
| What is the current revenue of Soleno Therapeutics? | Soleno Therapeutics's last 12 months revenue is $19.4M. |
| What is the current revenue growth of Soleno Therapeutics? | Soleno Therapeutics revenue growth (NTM/LTM) is 650%. |
| What is the current EV/Revenue multiple of Soleno Therapeutics? | Current revenue multiple of Soleno Therapeutics is 178.2x. |
| Is Soleno Therapeutics profitable? | Yes, Soleno Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
